StockWatch
·

BIOCON LTD. Q2 FY27 Results

BIOCONQ2 FY27 Results
Filing
Result:Weak· Market: Flat#Margin squeeze#Debt reduction

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue4.4K1.2%2.2%
Total Income4.4K0.8%0.8%
Expenditure4.4K2.6%3.7%
PBT54.8057.0%68.0%
Net Profit56.7058.5%57.3%
OPM18.78%0.45pp0.39pp
NPM1.28%1.84pp1.75pp
EPS0.2571.3%62.1%
View full financials

Core biosimilars segment revenue grew only 3.2% YoY while segment PBT collapsed 80.6% on cost inflation, making adjusted PAT decline ~56% a genuine operating deterioration despite modest top-line growth and continued debt paydown.

BIOCON LTD. · Q2 FY27 · THE VERDICT

The ₹56.7 Crore Profit Biocon Can't Explain

Reported PAT collapsed 57% YoY to ₹56.7 Cr (1.3% NPM), yet management claimed biosimilar EBITDA margins of 22%. The gap—more than 20 percentage points—remains unreconciled. Logistics deferral and freight costs explain part of it, but not the magnitude.

11 Nov 2026 · 6 min read
Reported PAT

₹56.7 Cr

-57.3% YoY

Claimed biosimilar EBITDA

₹623 Cr

22% margin

Unreconciled margin delta

~20pp

NPM 1.3% vs EBITDA 22%

On paper, Q2 revenue of ₹4,389 Cr grew 2.2% YoY, a soft miss against mid-teens guidance from the prior quarter. But the real story is profit: PAT crashed 57.3% to ₹56.7 Cr, compressing net margins to 1.3%. Management blamed a ~₹135 Cr (~5%) logistics deferral and freight/solvent cost headwinds, but the magnitude of margin collapse—from claimed 22% EBITDA on biosimilars to 1.3% NPM company-wide—leaves a 20-percentage-point gap that no one adequately explained on the call.

Where the profit went

Q2 FY27, ₹ Cr
01,048.692,097.393,146.082,809Biosimilars revenue623Claimed EBITDA56.7Reported group PAT
Management claimed ₹623 Cr EBITDA (22% margin) on biosimilars alone, yet group PAT was ₹56.7 Cr (1.3% NPM). Freight (~$5 Cr), solvents (~$5 Cr), and ₹135 Cr deferral cited, but the gap persists.

Claims vs. what holds up

Management's narrative, graded
  • "Biosimilar margins at mid-20s EBITDA"

  • "Underlying business remains strong"

  • "Yesafili off to encouraging start with 34% US market share"

  • "5% deferral is one-off Q2 situation, booked in October"

  • "H2 biosimilars to show double-digit growth"

The first two claims collapse under scrutiny. Q2 delivered 2.2% revenue growth YoY and -57.3% PAT decline—neither 'strong'—and the PAT number directly contradicts the mid-20s margin assertion. Yesafili's 34% US market share and >50% market access are credible and represent genuine momentum, as do the five new European biosimilar launches (Ustekinumab, Denosumab, Aflibercept, Aspart, Bevacizumab) gaining 20 tender awards. The deferral story—₹135 Cr logistics delay, shipments made but revenue unrecognized until October—is plausible and management stood by it. But the H2 'double-digit growth' guidance, offered without numeric PAT or margin targets, leaves execution risk elevated.

What changed on this call

Positive: Brazil Pertuzumab partnership closed (₹400 Cr over 10 years, supplies begin Q4 FY27)—a material, multi-year revenue floor not present prior. Five new biosimilar European launches imminent with 20 tender awards; Pebrizo (Pertuzumab) EU/UK launch Q1 2027, US Q3 2028; regulatory risk de-risked via Genentech settlement. Syngene sequential improvement from Q1, margin recovery trajectory intact.

Negative: H1 biosimilar growth 9% YoY (vs. mid-teens prior guidance)—a meaningful undershoot. Q2 deferral and margin collapse signal supply chain stress during a period of claimed launch readiness. No new numeric targets for FY27 biosimilar margins or FY28 PAT; prior 'mid-20s margin' guidance not reaffirmed verbally, though not withdrawn. Analysts pressed hard on margin bridge; management's answer (deferral + freight) insufficiently explained the 20pp gap.

How the street is positioned

The stock has lost 24.5% from its all-time high of ₹487.75, trading now at ₹368.05, roughly at its 50-day SMA (₹368.06) but below the 200-day (₹390.06). Technically, this is a pullback into support, not a crash—RSI at 58.2 is neutral, volume normal. But institutional positioning tells a nuanced story: FII ownership inched up to 8.14% from 7.52% last quarter (+0.62pp), suggesting conviction holders not fleeing. DII edged down (-0.69pp) to 23.38%, while promoter ownership remained stable at 44.68%. Most telling: in recent block deals, institutional buyers (SBI MF, HDFC MF, ICICI Prudential, Société Générale) accumulated at ₹400, while Mylan divested the same size at the same price. That's institutional confidence—buying weakness, not panic selling.

The bull-bear ledger

  • Brazil ₹400 Cr partnership concrete, multi-year revenue floor

  • Five new biosimilar launches with regulatory clarity (Pebrizo timeline confirmed)

  • Yesafili 34% US market share, >50% market access, surpassing originators

  • Syngene profitability inflection underway (18.5% EBITDA margin H1, track to mid-20s FY28)

  • Interest cost declining 12% YoY, balance sheet strengthening

  • PAT collapsed 57.3% YoY, margin guidance not reaffirmed, credibility tested

  • Q2 logistics deferral signals supply chain fragility during new launch ramps

  • H1 biosimilar growth 9% YoY vs. mid-teens guidance—execution lag

  • Biosimilar EBITDA-to-PAT bridge remains unreconciled; unaccounted items suspected

  • H2 'double-digit growth' claimed but no numeric margin or PAT targets given

Risks, ranked by severity to holders

What keeps analysts awake

Margin compression vs. EBITDA claims

High

Q2 PAT 1.3% vs. claimed biosimilar EBITDA 22%. Gap unreconciled and larger than deferral + freight explains. If this persists, mid-20s FY27 margin target is unrealistic; earnings power significantly lower.

New product execution on five launches

High

Yesafili, Aspart, Denosumab, Bevacizumab, Ustekinumab ramps must achieve claimed pricing and market share. Any delayed adoption or competitive entry erodes H2 acceleration narrative. Analysts pressed hard; management deferred customer detail offline.

Supply chain fragility

Medium

₹135 Cr Q2 deferral due to logistics/geopolitical delays. Booked in Oct, but pattern suggests just-in-time vulnerabilities during ramp phases. Further disruptions could cascade into H2 and Q3 revenue recognition.

Biosimilar ASP erosion from competitive entry

Medium

Yesafili, Aspart in crowded biosimilar market; Sandoz, Teva, other competitors entering via Part B/D routes. Management defended on 'value not price' but industry-wide pricing pressure visible. Durability of 34% Yesafili share unproven.

Currency headwinds

Medium

Management cited 6–8% FX benefit but rupee depreciation not guaranteed. Adverse movement compresses reported margins; generics particularly exposed to crude-linked input costs.

Generics margin recovery stalling

Low-Medium

H1 EBITDA margin 8%, up from 1%, but this recovery not yet flowing to PAT. Freight/solvent easing will help, but API/formulations ASP pressure remains. Syngene client consolidation (post-Viatris) is a future headwind.

The debate

The honest read: Biocon is in a structural inflection—five new launches, a landmark Brazil deal, and Syngene recovery are genuine. But Q2's execution gap (promised growth, delivered stall; claimed margins, showed collapse) has tested credibility. The margin bridge remains unexplained, and management's refusal to reaffirm numeric targets is a tell. This is not a broken story, but it's not a clear buy at current weakness either. Holders should see H2 as a proof point: if biosimilar growth does hit double-digits and margins recover to high-teens, the stock rebounds and the bulls win. If H2 stumbles, -24.5% from ATH looks cheap in retrospect.

What to watch next
  • 1 · H2 FY27 biosimilar growth rate (Q3 / Q4 updates)

    Management guided 'double-digit growth' but gave no numeric target. Watch for incremental quarterly guidance, tender award announcements, and Yesafili/Aspart inventory build signals. If 9% YoY H1 accelerates to 15%+ in H2, the narrative holds. If it stalls near 10%, execution risk is real.

  • 2 · Q3 margin bridge / PAT recovery

    The ₹135 Cr deferral was booked in October (Q3). Watch whether Q3 PAT rebounds meaningfully once this revenue lands. If Q3 PAT stays compressed despite deferral recognition, the unaccounted 20pp margin gap becomes a structural issue, not a one-off.

  • 3 · Brazil Pertuzumab ramp and Pebrizo EU/UK launch (Q4 / Q1 2027)

    First supplies to Bahiafarma/Bionov in Q4 FY27, then Pebrizo commercial availability EU/UK in Q1 2027. Any regulatory slippage or supply-side hiccups signal execution risk. Conversely, on-time launch confirms management's de-risking narrative.

Biocon is a steady business having a lumpy quarter, not a broken franchise. Long-term structural tailwinds (biosimilar adoption, manufacturing moat, geographic diversification) are real. But near-term credibility is on the line: claimed mid-20s margins are not materializing, guidance has been missed, and the supply chain hiccup (₹135 Cr deferral) is a warning sign during a period of supposed launch momentum.

The number to track from here is H2 biosimilar growth. If it hits 15%+ YoY and margins recover visibly, the -24.5% drawdown from ATH becomes a gift. If it stalls at 10% or below, execution risk migrates from 'medium' to 'high,' and the stock likely re-tests lower support. Holders should hold for the H2 print and Q3/Q4 catalysts; new buyers might wait for that proof point.

Informational and educational content only. Not investment advice.